Fibrocell to Host Conference Call & Webcast for Full Year 2018 Financial Results and Recent Highlights on March 27, 2019
20 Marzo 2019 - 6:00AM
- Company to provide update on Type B
meeting with FDA on Phase 3 clinical trial design for FCX-007
gene therapy candidate for recessive dystrophic epidermolysis
bullosa (RDEB) -
Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy company
focused on transformational autologous cell-based therapies for
skin and connective tissue diseases, today announced it will report
financial results for the year ended December 31, 2018 and
operational highlights on March 27, 2019 before the open of the
U.S. financial markets.
John Maslowski, President and Chief Executive
Officer of Fibrocell, will host a conference call and webcast at
8:30 a.m. EDT on the same day to discuss the Company’s financial
results. In addition, he will discuss the recent Type B
end-of-Phase 2 meeting with the U.S. Food and Drug Administration
regarding the Phase 3 clinical trial design for FCX-007,
Fibrocell’s gene therapy candidate for the treatment of RDEB.
Furthermore, Mr. Maslowski will provide additional data and address
progress from the ongoing Phase 1/2 clinical trial of FCX-007 for
the treatment of RDEB.
A corporate slide presentation will be
referenced during the call and will be posted in the Investors
section of the Company’s website www.fibrocell.com/investors/events
under the event, “2018 Financial Results & Recent Highlights.”
Following the presentation, there will be a question-and-answer
session with Mr. Maslowski and Alfred Lane, MD, Chief Medical
Advisor of Fibrocell and Professor of Dermatology and Pediatrics
(Emeritus) at the Stanford University School of Medicine.
Fibrocell Conference Call &
Webcast
To participate on the live call, please dial
888-394-8218 (domestic) or +1-323-794-2588 (international), and
provide the conference code 8315981 five to ten minutes before
the start of the call. The conference call will also be webcast
live under the investor relations section of Fibrocell's website at
www.fibrocell.com/investors/events and will be archived there for
30 days following the call.
About Fibrocell
Fibrocell is an autologous cell and gene therapy
company translating personalized biologics into medical
breakthroughs for diseases affecting the skin and connective
tissue. Fibrocell’s most advanced product candidate, FCX-007,
is the subject of a Phase 1/2 clinical trial for the treatment of
RDEB. Fibrocell is also developing FCX-013, the Company’s clinical
stage candidate for the treatment of moderate to severe localized
scleroderma. Fibrocell’s gene therapy portfolio is being
developed in collaboration with Intrexon Corporation (Nasdaq: XON),
a leader in synthetic biology. For more information, visit
www.fibrocell.com or follow Fibrocell on Twitter at @Fibrocell.
Trademarks
Fibrocell®, the Fibrocell logo, and Fibrocell
Science® are trademarks of Fibrocell Science, Inc. and/or its
affiliates. All other names may be trademarks of their
respective owners.
Investor & Media Relations Contact:Karen
Casey484-713-6133kcasey@fibrocell.com
Fibrocell Science (NASDAQ:FCSC)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Fibrocell Science (NASDAQ:FCSC)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024